Sarepta Therapeutics Inc (NASDAQ:SRPT)

149.65
Delayed Data
As of Jun 21
 -4.04 / -2.63%
Today’s Change
32.36
Today|||52-Week Range
176.50
+168.96%
Year-to-Date
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
Jun 20 / Zacks.com - Paid Partner Content
Options Traders Expect Huge Moves in Sarepta (SRPT) Stock
Jun 15 / Zacks.com - Paid Partner Content
Company News For Jun 20, 2018
Jun 20 / Zacks.com - Paid Partner Content
Sarepta Inks Manufacturing Deal for Gene Therapy Program
Jun 14 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close153.69
Today’s open156.50
Day’s range149.08 - 157.80
Volume2,450,960
Average volume (3 months)1,543,468
Market cap$6.1B
Data as of 4:00pm ET, 06/21/2018

Growth & Valuation

Earnings growth (last year)+84.34%
Earnings growth (this year)-147.13%
Earnings growth (next 5 years)+0.37%
Revenue growth (last year)+2,751.58%
P/E ratioNM
Price/Sales21.17
Price/Book7.64

Competitors

 Today’s
change
Today’s
% change
CBPOChina Biologic Produ...-0.11-0.11%
LOXOLoxo Oncology Inc+4.94+2.77%
RAREUltragenyx Pharmaceu...-2.96-3.47%
IRWDIronwood Pharmaceuti...+0.01+0.05%
Data as of 4:00pm ET, 06/21/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)-$0.77
Annual revenue (last year)$154.6M
Annual profit (last year)-$50.7M
Net profit margin-32.79%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Douglas S. Ingram
Executive VP, Chief Financial &
Business Officer
Sandesh Mahatme
Corporate headquarters
Cambridge, Massachusetts

Forecasts